TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23437787

Group type: EXPERIMENTAL
Intervention: Ablation catheter with 6 distal irrigation channels (6C)
Number of subjects: 296

Group type: COMPARATOR
Intervention: Ablation catheter with 12 distal irrigation channels (12C)
Number of subjects: 296
Study: 21475949

Group type: EXPERIMENTAL
Intervention: Alfuzosin (Alf) for 8 weeks
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Tamsulosin (Tam) for 8 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Alfuzosin (Alf) after Tamsulosin (Tam)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Tamsulosin (Tam) after Alfuzosin (Alf)
Number of subjects: 100
Study: 18353696

Group type: EXPERIMENTAL
Intervention: Oral sustained-release morphine (60 mg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl (0.6 mg, 25 microg/h)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Oral methadone (15 mg)
Number of subjects: 108
Study: 16084579

Group type: EXPERIMENTAL
Intervention: phonological rhyme generation paradigm
Number of subjects: 19

Group type: COMPARATOR
Intervention: classical word generation condition
Number of subjects: 19
Study: 15365277

Group type: EXPERIMENTAL
Intervention: Combination therapy including diuretics and agents that block angiotensin II
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination drug therapy
Number of subjects: 0
Study: 11505794

Group type: EXPERIMENTAL
Intervention: Jet injection of somatropin (8.64 IU)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cannula injection of somatropin (8.64 IU)
Number of subjects: 13
Study: 9284488

Group type: EXPERIMENTAL
Intervention: Solid meal
Number of subjects: 10

Group type: COMPARATOR
Intervention: Liquid meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Mixed meal
Number of subjects: 10
Study: 7682088

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (12 g/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose methotrexate (6 g/m2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ifosfamide (added to chemotherapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraarterial cisplatinum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Limb-salvage procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alternative postsurgical chemotherapy for poor responders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Late sequelae of chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exploration of drug administration methods
Number of subjects: 0
Study: 3803252

Group type: EXPERIMENTAL
Intervention: Cefadroxil 1 g every 12 hours for 10 days
Number of subjects: 103

Group type: COMPARATOR
Intervention: Cefaclor 500 mg every 8 hours for 10 days
Number of subjects: 103
Study: 31067018

Group type: EXPERIMENTAL
Intervention: 30-minute one-to-one structured brief intervention with a trained learning mentor and an alcohol leaflet
Number of subjects: 443

Group type: COMPARATOR
Intervention: Healthy lifestyle leaflet (no alcohol information)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of the brief intervention
Number of subjects: 443
Study: 29493785

Group type: EXPERIMENTAL
Intervention: Intracutaneous suturing (IC)
Number of subjects: 339

Group type: COMPARATOR
Intervention: Transcutaneous suturing (TC)
Number of subjects: 339
Study: 27137950

Group type: EXPERIMENTAL
Intervention: Isometric handgrip (IHG) training (4, 2-min unilateral contractions at 30% of maximal voluntary contraction, 3 days per week for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study: 24886064

Group type: EXPERIMENTAL
Intervention: Tenecteplase 0.4 mg/kg (single bolus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alteplase 0.9 mg/kg (10% bolus + 90% infusion/60 minutes)
Number of subjects: 0
Study: 22192144

Group type: EXPERIMENTAL
Intervention: AZD8309
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 20430947

Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg/d)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Valsartan (160 mg/d)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Combination of amlodipine and valsartan
Number of subjects: 108
Study: 17663296

Group type: EXPERIMENTAL
Intervention: 14-week combined dietary-behavioral-physical activity intervention
Number of subjects: 54
Study: 16059623

Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 4011

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4011
Study: 11966765

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 68

Group type: COMPARATOR
Intervention: Discontinuation of HAART
Number of subjects: 68
Study: 10425465

Group type: EXPERIMENTAL
Intervention: Oral oestradiol and norethisterone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Parenteral oestradiol and norethisterone
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Oral oestradiol
Number of subjects: 14
Study: 8869018

Group type: EXPERIMENTAL
Intervention: Abciximab (c7E3) administered at the time of angioplasty or directional coronary atherectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abciximab (c7E3)
Number of subjects: 0
Study: 2406891

Group type: EXPERIMENTAL
Intervention: Selective Proximal Vagotomy (SPV)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Selective Proximal Vagotomy + Pyloroplasty (SPV + PP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cholecystectomized patients
Number of subjects: 60
Study: 7467371

Group type: EXPERIMENTAL
Intervention: Isoket-spray (3.75 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo-spray
Number of subjects: 40
Study: 30875097

Group type: EXPERIMENTAL
Intervention: NSS powder (1 g/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30400846

Group type: EXPERIMENTAL
Intervention: Close contact experience with individuals with mental illness
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Non-close contact experience with individuals with mental illness
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Agreeableness and openness to experience
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Extraversion
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Conscientiousness and neuroticism
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Openness to experience
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Agreeableness
Number of subjects: 1002
Study: 26566200

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS) in patients with tremor-predominant Parkinson disease (PD)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Deep brain stimulation (DBS)
Number of subjects: 4
Study: 24745865

Group type: EXPERIMENTAL
Intervention: Acupuncture stimulation on PC6 and L14 points (combined group)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Acupuncture stimulation on PC6 point only (single group)
Number of subjects: 227
Study: 22229880

Group type: EXPERIMENTAL
Intervention: Marriage education (PREP)
Number of subjects: 662

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 662
Study: 19605598

Group type: EXPERIMENTAL
Intervention: MRKAd6 HIV type 1 (HIV‐1) trigene vaccine at weeks 0, 4, and 26
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: MRKAd5+MRKAd6 (MRKAd5+6) HIV‐1 trigene vaccine at weeks 0, 4, and 26
Number of subjects: 34
Study: 17495495

Group type: COMPARATOR
Intervention: Lithotomy position (group 1)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lateral position (group 2)
Number of subjects: 70
Study: 15210599

Group type: EXPERIMENTAL
Intervention: CPR
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CPR (duration >3 minutes)
Number of subjects: 105
Study: 12402055

Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (2 Gy/day for a total of 70 Gy)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Combination of external beam radiotherapy (50 Gy, 2 Gy/day) and high dose rate brachytherapy (two 10-Gy fractions)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 10
Study: 10451461

Group type: EXPERIMENTAL
Intervention: Vitamin D (600,000 U intramuscularly at enrollment and at 12 weeks)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Calcium (1000 mg daily)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Combination therapy (Vitamin D and Calcium)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (children without rickets)
Number of subjects: 123
Study: 7587987

Group type: EXPERIMENTAL
Intervention: Mometasone furoate (Elocon)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (Cutivate)
Number of subjects: 0
Study: 2141491

Group type: EXPERIMENTAL
Intervention: Megestrol Acetate (MA) 2 X 80 mg p.o. daily
Number of subjects: 98

Group type: COMPARATOR
Intervention: Medroxyprogesterone Acetate (MPA) 2 X 500 mg p.o. daily
Number of subjects: 98
Study: 695649

Group type: EXPERIMENTAL
Intervention: Perhexiline
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30548844

Group type: EXPERIMENTAL
Intervention: Hemofiltration for 36 hours
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 37
Study: 28218483

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate with alcohol (CHX+)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate without alcohol (CHX-)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sterile flavoured-mint physiological saline (control)
Number of subjects: 20
Study: 25422168

Group type: EXPERIMENTAL
Intervention: Educational needs assessment tool-focused education
Number of subjects: 16

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16
Study: 23350644

Group type: EXPERIMENTAL
Intervention: 200 IU vitamin D daily (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D monthly (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D every 2 weeks (Group C)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 120
Study: 22178838

Group type: EXPERIMENTAL
Intervention: Group I: 14 Fr silicon tube (Urovision) with balloon
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Group II: 14 Fr silicon tube (Urovision) without balloon
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Group III: 20 Fr latex tube without balloon
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control: Not applicable
Number of subjects: 72
Study: 19690349

Group type: EXPERIMENTAL
Intervention: AZD0837 (150 mg once daily)
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: AZD0837 (300 mg once daily)
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: AZD0837 (200 mg twice daily)
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: AZD0837 (450 mg once daily)
Number of subjects: 955

Group type: EXPERIMENTAL
Intervention: AZD0837 (150, 300, 450 mg once daily or 200 mg twice daily)
Number of subjects: 955

Group type: COMPARATOR
Intervention: VKA (international normalized ratio 2‐3, target 2.5)
Number of subjects: 955

Group type: COMPARATOR
Intervention: VKA
Number of subjects: 955
Study: 16456412

Group type: EXPERIMENTAL
Intervention: Nominal starting dose of PEG 4000
Number of subjects: 96

Group type: COMPARATOR
Intervention: Double starting dose of PEG 4000
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: PEG 4000 treatment
Number of subjects: 96
Study: 17136986

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg daily
Number of subjects: 2128

Group type: EXPERIMENTAL
Intervention: Tiotropium 36 mcg daily
Number of subjects: 2128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2128
Study: 15550144

Group type: EXPERIMENTAL
Intervention: Imiquimod (5 days per week for 1, 2, or 4 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (2 weeks)
Number of subjects: 16
Study: 10404354

Group type: EXPERIMENTAL
Intervention: Losartan (12.5 mg, titrated to 50 mg once daily)
Number of subjects: 3152

Group type: COMPARATOR
Intervention: Captopril (12.5 mg, titrated to 50 mg thrice daily)
Number of subjects: 3152
Study: 8603160

Group type: EXPERIMENTAL
Intervention: soaking cleanser at 50 degrees C
Number of subjects: 80

Group type: COMPARATOR
Intervention: toothbrush/paste
Number of subjects: 80

Group type: COMPARATOR
Intervention: brush with soap and water
Number of subjects: 80

Group type: COMPARATOR
Intervention: all materials
Number of subjects: 80
Study: 2390397

Group type: EXPERIMENTAL
Intervention: High intensity training programme for one year
Number of subjects: 40

Group type: COMPARATOR
Intervention: Atenolol (beta blocker)
Number of subjects: 40
Study: 7013510

Group type: EXPERIMENTAL
Intervention: Cryoprecipitated plasma
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Plasma protein fraction
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Serum albumin solution
Number of subjects: 176
Study: 29723001

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation app
Number of subjects: 238

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 238
Study: 28107807

Group type: EXPERIMENTAL
Intervention: Continuous theta-burst stimulation (cTBS) at 80% resting motor threshold
Number of subjects: 12

Group type: COMPARATOR
Intervention: Active control group receiving cTBS at 40% resting motor threshold
Number of subjects: 12
Study: 25886554

Group type: EXPERIMENTAL
Intervention: Rights-based curriculum
Number of subjects: 1750

Group type: COMPARATOR
Intervention: Basic sex education (control) curriculum
Number of subjects: 1750
Study: 24176451

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 8943

Group type: EXPERIMENTAL
Intervention: Nateglinide
Number of subjects: 8943

Group type: COMPARATOR
Intervention: Control (no valsartan, no nateglinide)
Number of subjects: 8943

Group type: EXPERIMENTAL
Intervention: Baseline fasting glucose increment
Number of subjects: 8943

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 8943
Study: 21377656

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 19450912

Group type: EXPERIMENTAL
Intervention: Coping with Depression course (CWD)
Number of subjects: 25
Study: 17846945

Group type: EXPERIMENTAL
Intervention: Combined temporal clear corneal phacoemulsification and limbal relaxing incisions (LRIs)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Temporal clear corneal phacoemulsification
Number of subjects: 62
Study: 15472775

Group type: EXPERIMENTAL
Intervention: Curettage and autologous bone grafting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Homologous bone grafting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mixed autologous-homologous bone grafting
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Curettage only
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (asymptomatic patients)
Number of subjects: 12
Study: 11547366

Group type: EXPERIMENTAL
Intervention: All-polyethylene tibial components
Number of subjects: 48

Group type: COMPARATOR
Intervention: Metal-backed tibial components
Number of subjects: 48
Study: 9603382

Group type: EXPERIMENTAL
Intervention: First Definite Apical Clearance Lens (FDACL)
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Steep keratometric reading
Number of subjects: 1209

Group type: EXPERIMENTAL
Intervention: Flat keratometric reading
Number of subjects: 1209
Study: 7826785

Group type: EXPERIMENTAL
Intervention: Alfentanil 5 micrograms kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms kg‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micrograms kg‐1
Number of subjects: 60
Study: 29044915

Group type: EXPERIMENTAL
Intervention: Pre-discharge troponin elevation (>0.04 ng/mL)
Number of subjects: 1469

Group type: EXPERIMENTAL
Intervention: 1-month troponin elevation (>0.04 ng/mL)
Number of subjects: 1469
Study: 27525531

Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (150 μg levonorgestrel and 30 μg ethinylestradiol)
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 25380007

Group type: EXPERIMENTAL
Intervention: Negative-pressure wound therapy
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard open wound care
Number of subjects: 49
Study: 23422754

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus docetaxel
Number of subjects: 736

Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 736
Study: 19901115

Group type: EXPERIMENTAL
Intervention: gemcitabine + pertuzumab
Number of subjects: 130

Group type: COMPARATOR
Intervention: gemcitabine + placebo
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: gemcitabine + pertuzumab (in patients with low HER3 mRNA expression)
Number of subjects: 130
Study: 18212333

Group type: EXPERIMENTAL
Intervention: Social interaction (10 min)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social interaction (amount of actual social contact)
Number of subjects: 0
Study: 17008561

Group type: EXPERIMENTAL
Intervention: Oxford House
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual-care condition (outpatient treatment or self-help groups)
Number of subjects: 150
Study: 14753595

Group type: EXPERIMENTAL
Intervention: STI‐571 (Gleevec)
Number of subjects: 7
Study: 11079255

Group type: EXPERIMENTAL
Intervention: MUFA diet (39% of energy as fat and 21 E% monoenes)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Reduced-fat diet (34 E% fat, 16 E% monoenes)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both diets compared to baseline diet (high in saturated fat)
Number of subjects: 18
Study: 8844228

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 1.5 mg/kg per h continuously for 5 days after a loading dose of 600 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Saline solution as placebo (control)
Number of subjects: 52
Study: 1581786

Group type: EXPERIMENTAL
Intervention: Impedance plethysmography
Number of subjects: 193
Study: 3922068

Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate nasal spray (group 1)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 2% sodium cromoglycate plus 0.2% chlorpheniramine nasal spray (group 2)
Number of subjects: 51
Study: 31479035

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Combined Training (CT)
Number of subjects: 24
Study: 29345398

Group type: EXPERIMENTAL
Intervention: Music therapy (self-selected music using ear-bud headphones during the procedure)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no music during the procedure)
Number of subjects: 60
Study: 27015667

Group type: EXPERIMENTAL
Intervention: Splint removal on the 3rd day after septoplasty
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Splint removal on the 5th day after septoplasty
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Splint removal on the 7th day after septoplasty
Number of subjects: 109
Study: 24400593

Group type: EXPERIMENTAL
Intervention: Self-administered method (three-minute pressure to sciatic nerves applied by patients themselves)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Hand pressure method (three-minute pressure to sciatic nerves applied by hands)
Number of subjects: 172
Study: 22845895

Group type: EXPERIMENTAL
Intervention: bup100 (300 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: pla (200 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: bup50 (150 mg) and bup75 (225 mg)
Number of subjects: 10
Study: 19931549

Group type: EXPERIMENTAL
Intervention: 40 mg cortisol (administered in a double-blind, placebo-controlled crossover design)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18817234

Group type: EXPERIMENTAL
Intervention: Lidocaine (20 mL of 2% lidocaine and 0.9% saline)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 166
Study: 16274097

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg/day for 4 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15493242

Group type: EXPERIMENTAL
Intervention: SP/LPA (speech discrimination, letter‐sound correspondence, and phonemic awareness)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: LPA (letter‐sound correspondence and phonemic awareness)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 10207461

Group type: EXPERIMENTAL
Intervention: Morphine
Number of subjects: 340

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 340
Study: 7868909

Group type: EXPERIMENTAL
Intervention: IL‐1 and IL‐1 receptor antagonist (IL‐1ra) production in IBD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL‐1ra/IL‐1 ratio
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-limiting colitis patients
Number of subjects: 0
Study: 1720336

Group type: EXPERIMENTAL
Intervention: Colloids (6% HES 200/0.5)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Crystalloids (Ringer's solution)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Colloid replacement with hemofiltration (HF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Colloid replacement with cell saver (CS)
Number of subjects: 60
Study: 348294

Group type: EXPERIMENTAL
Intervention: CCNU
Number of subjects: 109

Group type: COMPARATOR
Intervention: methyl‐CCNU
Number of subjects: 109
Study: 29571271

Group type: EXPERIMENTAL
Intervention: Cancer Home‐Life Intervention
Number of subjects: 242
Study: 30685834

Group type: EXPERIMENTAL
Intervention: Subarachnoid anesthesia with ketamine 0.75 mg/kg (KE0.75)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Subarachnoid anesthesia with ketamine 1.5 mg/kg (KE1.5)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Subarachnoid anesthesia with ketamine
Number of subjects: 90